Consensus Ashland Inc.

Stocks

ASH

US0441861046

Diversified Chemicals

Market Closed - NYSE 01:30:03 12/09/2026 am IST			5-day change	1st Jan Change
70.91 ^USD	+0.30%		-2.77%	+20.86%

24/08	Ashland Inc. Launches Permexa Sodium Caprate to Support Scalable Development and Commercialization of Oral Peptide, Biologic and Low-Permeability Drug Products	CI
13/08	Ancora offers up to $1.2bn for an H.B. Fuller business

Evolution of the Average Target: Ashland Inc.

Evolution of the Target Price: Ashland Inc.

Changes in Analyst Recommendations: Ashland Inc.

a8a3d2305a.KcisTV97U4Ng-cTPXe7x9YCk0jRAL3w5pBIoJ9qX7UE.QIH7OBYWBfYLmoKaCKbHo-PglFwpQAxVnWp6FJTtp3F7v-8FGSwYuyO7pw~7fac0aae743452cda0b93f01840a7542

Analysts' recommendations: Ashland Inc.

06/08	Ashland's Fundamentals Appear to Improve With a Fiscal Q3 Beat, Morgan Stanley Says	MT
06/08	Morgan Stanley Adjusts Price Target on Ashland to $78 From $58, Maintains Equalweight Rating	MT
31/07	Deutsche Bank Adjusts Ashland Price Target to $85 From $74, Maintains Buy Rating	MT
30/07	UBS Adjusts Price Target on Ashland to $83 From $75, Maintains Buy Rating	MT
15/06	Deutsche Bank Adjusts Ashland Price Target to $74 From $60, Maintains Buy Rating	MT
10/06	UBS Lifts Ashland Price Target to $72 From $66, Maintains Buy Rating	MT
06/05	Seaport Upgrades Ashland to Buy From Neutral, Sets $75 Price Target	MT
04/05	Ashland's Fiscal Q2 a 'Mixed Bag' With Downward EBITDA Revisions, Morgan Stanley Says	MT
04/05	Morgan Stanley Lowers Price Target on Ashland to $58 From $63, Keeps Equalweight Rating	MT
06/04	Mizuho Cuts Price Target on Ashland to $65 From $70, Keeps Outperform Rating	MT
04/02	UBS Adjusts Price Target on Ashland to $73 From $70, Maintains Buy Rating	MT
04/02	Deutsche Bank Adjusts Ashland Price Target to $70 From $58, Maintains Buy Rating	MT
12/01	UBS Adjusts Price Target on Ashland to $70 From $64, Maintains Buy Rating	MT
18/12	Mizuho Securities Adjusts Ashland Price Target to $70 From $60, Maintains Outperform Rating	MT
16/12	Ashland Shares Rise After BMO Capital Upgrade	MT
15/12	BMO Capital Upgrades Ashland to Outperform From Market Perform, Adjusts PT to $71 From $61	MT
12/11	Deutsche Bank Raises Price Target on Ashland to $58 From $55, Keeps Buy Rating	MT
03/25/03	Mizuho Lowers Price Target on Ashland to $54 From $58, Keeps Outperform Rating	MT
30/25/30	Deutsche Bank Cuts Price Target on Ashland to $55 From $62, Keeps Buy Rating	MT
08/25/08	Morgan Stanley Initiates Coverage on Ashland With Equal Weight Rating, $60 Price Target	MT
07/25/07	UBS Adjusts Price Target on Ashland to $64 From $73, Maintains Buy Rating	MT
09/25/09	UBS Trims Price Target on Ashland to $73 From $74, Maintains Buy Rating	MT
02/25/02	Wells Fargo Downgrades Ashland to Equalweight From Overweight, Adjusts Price Target to $50 From $58	MT
01/25/01	UBS Adjusts Price Target on Ashland to $74 From $85, Maintains Buy Rating	MT
26/25/26	JPMorgan Upgrades Ashland to Overweight From Neutral, Adjusts Price Target to $71 From $68	MT

More recommendations

Diversified Chemicals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ASHLAND INC.					+13.08%
	SHIN-ETSU CHEMICAL CO., LTD.					+35.5%
	BASF SE					+1.34%
	PIDILITE INDUSTRIES LIMITED					+14%
	ASAHI KASEI CORPORATION					+26.5%
	MITSUBISHI CHEMICAL GROUP CORPORATION					+7.53%
	BRENNTAG SE					-4.76%
	SYENSQO SA/NV					+2.49%
	SASOL LIMITED					-8.48%
	SRF LIMITED					+17.51%
	Average					+10.47%
	Weighted average by Cap.					+16.28%